메뉴 건너뛰기




Volumn 8, Issue , 2016, Pages 127-140

Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: Current perspectives

Author keywords

Correctors; Drug repositioning; High throughput screening; Personalized medicine; Potentiators; Precision medicine

Indexed keywords

ABBV 974; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ATALUREN; CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLPG 1837; IBUPROFEN; IVACAFTOR; IVACAFTOR PLUS LUMACAFTOR; LUMACAFTOR; N 91115; PHOSPHODIESTERASE V INHIBITOR; QBW 251; RESPIRATORY TRACT AGENT; RIOCIGUAT; SILDENAFIL; TEZACAFTOR; UNCLASSIFIED DRUG; VARDENAFIL;

EID: 84992109815     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S100759     Document Type: Review
Times cited : (50)

References (171)
  • 1
    • 0024424270 scopus 로고
    • Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA
    • Riordan J, Rommens J, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-1073.
    • (1989) Science , vol.245 , Issue.4922 , pp. 1066-1073
    • Riordan, J.1    Rommens, J.2    Kerem, B.3
  • 2
    • 84878464222 scopus 로고    scopus 로고
    • Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis
    • Huaux F, Noel S, Dhooghe B, et al. Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis. PLoS One. 2013;8(5):e64341.
    • (2013) Plos One , vol.8 , Issue.5
    • Huaux, F.1    Noel, S.2    Dhooghe, B.3
  • 3
    • 84921029693 scopus 로고    scopus 로고
    • Cystic fibrosis transmembrane conductance regulator protein (CFTR) expression in the developing human brain: Comparative immunohis-tochemical study between patients with normal and mutated CFTR.
    • Marcorelles P, Friocourt G, Uguen A, Ledé F, Férec C, Laquerrière A. Cystic fibrosis transmembrane conductance regulator protein (CFTR) expression in the developing human brain: comparative immunohis-tochemical study between patients with normal and mutated CFTR. J Histochem Cytochem. 2014;62(11):791-801.
    • (2014) J Histochem Cytochem , vol.62 , Issue.11 , pp. 791-801
    • Marcorelles, P.1    Friocourt, G.2    Uguen, A.3    Ledé, F.4    Férec, C.5    Laquerrière, A.6
  • 4
    • 33845743367 scopus 로고    scopus 로고
    • Evidence for cystic fibrosis transmembrane conductance regulator chloride current in swine ventricular myocytes
    • Gao Z, Sun HY, Lau CP, Chin-Wan Fung P, Li GR. Evidence for cystic fibrosis transmembrane conductance regulator chloride current in swine ventricular myocytes. J Mol Cell Cardiol. 2007;42(1):98-105.
    • (2007) J Mol Cell Cardiol , vol.42 , Issue.1 , pp. 98-105
    • Gao, Z.1    Sun, H.Y.2    Lau, C.P.3    Chin-Wan Fung, P.4    Li, G.R.5
  • 5
    • 84868322168 scopus 로고    scopus 로고
    • Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection
    • Bonfield TL, Hodges CA, Cotton CU, Drumm ML. Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection. J Leukoc Biol. 2012;92(5):1111-1122.
    • (2012) J Leukoc Biol , vol.92 , Issue.5 , pp. 1111-1122
    • Bonfield, T.L.1    Hodges, C.A.2    Cotton, C.U.3    Drumm, M.L.4
  • 6
    • 33748146503 scopus 로고    scopus 로고
    • CFTR regulates phagosome acidification in macrophages and alters bactericidal activity
    • Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol. 2006;8(9):933-944.
    • (2006) Nat Cell Biol , vol.8 , Issue.9 , pp. 933-944
    • Di, A.1    Brown, M.E.2    Deriy, L.V.3
  • 7
    • 33748654201 scopus 로고    scopus 로고
    • CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis
    • Painter RG, Valentine VG, Lanson NA, et al. CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry. 2006;45(34):10260-10269.
    • (2006) Biochemistry , vol.45 , Issue.34 , pp. 10260-10269
    • Painter, R.G.1    Valentine, V.G.2    Lanson, N.A.3
  • 8
  • 9
    • 0022350960 scopus 로고
    • Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker
    • Tsui L, Buchwald M, Barker D, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science. 1985;230(4729): 1054-1057.
    • (1985) Science , vol.230 , Issue.4729 , pp. 1054-1057
    • Tsui, L.1    Buchwald, M.2    Barker, D.3
  • 10
    • 33645307384 scopus 로고    scopus 로고
    • The ABC protein turned chloride channel whose failure causes cystic fibrosis
    • Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature. 2006;440(7083): 477-483.
    • (2006) Nature , vol.440 , Issue.7083 , pp. 477-483
    • Gadsby, D.C.1    Vergani, P.2    Csanady, L.3
  • 11
    • 84880428551 scopus 로고    scopus 로고
    • Origin and evolution of the cystic fibrosis transmembrane regulator protein R domain
    • Sebastian A, Rishishwar L, Wang J, et al. Origin and evolution of the cystic fibrosis transmembrane regulator protein R domain. Gene. 2013;523(2): 137-146.
    • (2013) Gene , vol.523 , Issue.2 , pp. 137-146
    • Sebastian, A.1    Rishishwar, L.2    Wang, J.3
  • 12
    • 0025987020 scopus 로고
    • Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel
    • Cheng SH, Rich DP, Marshall J, Gregory RJ, Welsh MJ, Smith AE. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell. 1991;66(5):1027-1036.
    • (1991) Cell , vol.66 , Issue.5 , pp. 1027-1036
    • Cheng, S.H.1    Rich, D.P.2    Marshall, J.3    Gregory, R.J.4    Welsh, M.J.5    Smith, A.E.6
  • 13
    • 20844457435 scopus 로고    scopus 로고
    • Preferential phosphorylation of R-domain Serine 768 dampens activation of CFTR channels by PKA.
    • Csanády L, Seto-Young D, Chan KW, et al. Preferential phosphorylation of R-domain Serine 768 dampens activation of CFTR channels by PKA. J Gen Physiol. 2005;125(2):171-186.
    • (2005) J Gen Physiol , vol.125 , Issue.2 , pp. 171-186
    • Csanády, L.1    Seto-Young, D.2    Chan, K.W.3
  • 14
    • 84965089611 scopus 로고    scopus 로고
    • Regulation of the cystic fibrosis transmembrane conductance regulator anion channel by tyrosine phosphorylation
    • Billet A, Jia Y, Jensen T, Riordan JR, Hanrahan JW. Regulation of the cystic fibrosis transmembrane conductance regulator anion channel by tyrosine phosphorylation. FASEB J. 2015;29(9):3945-3953.
    • (2015) FASEB J , vol.29 , Issue.9 , pp. 3945-3953
    • Billet, A.1    Jia, Y.2    Jensen, T.3    Riordan, J.R.4    Hanrahan, J.W.5
  • 15
    • 0037404448 scopus 로고    scopus 로고
    • Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells
    • Hallows KR, Kobinger GP, Wilson JM, Witters LA, Foskett JK. Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells. Am J Physiol Cell Physiol. 2003;284(5):C1297-C1308.
    • (2003) Am J Physiol Cell Physiol , vol.284 , Issue.5 , pp. C1297-C1308
    • Hallows, K.R.1    Kobinger, G.P.2    Wilson, J.M.3    Witters, L.A.4    Foskett, J.K.5
  • 16
    • 57349092525 scopus 로고    scopus 로고
    • PKC phosphorylation modulates PKA-dependent binding of the R domain to other domains of CFTR
    • Seavilleklein G, Amer N, Evagelidis A, et al. PKC phosphorylation modulates PKA-dependent binding of the R domain to other domains of CFTR. Am J Physiol Cell Physiol. 2008;295(5):C1366-C1375.
    • (2008) Am J Physiol Cell Physiol , vol.295 , Issue.5 , pp. C1366-C1375
    • Seavilleklein, G.1    Amer, N.2    Evagelidis, A.3
  • 17
    • 0033817333 scopus 로고    scopus 로고
    • Severed channels probe regulation of gating of cystic fibrosis transmembrane conductance regulator by its cytoplasmic domains
    • Csanády L, Chan KW, Seto-Young D, Kopsco DC, Nairn AC, Gadsby DC. Severed channels probe regulation of gating of cystic fibrosis transmembrane conductance regulator by its cytoplasmic domains. J Gen Physiol. 2000;116(3):477-500.
    • (2000) J Gen Physiol , vol.116 , Issue.3 , pp. 477-500
    • Csanády, L.1    Chan, K.W.2    Seto-Young, D.3    Kopsco, D.C.4    Nairn, A.C.5    Gadsby, D.C.6
  • 18
    • 23844483240 scopus 로고    scopus 로고
    • Phosphorylation of CFTR by PKA promotes binding of the regulatory domain
    • Chappe V, Irvine T, Liao J, Evagelidis A, Hanrahan JW. Phosphorylation of CFTR by PKA promotes binding of the regulatory domain. EMBO J. 2005;24(15):2730-2740.
    • (2005) EMBO J , vol.24 , Issue.15 , pp. 2730-2740
    • Chappe, V.1    Irvine, T.2    Liao, J.3    Evagelidis, A.4    Hanrahan, J.W.5
  • 19
  • 20
    • 0030816586 scopus 로고    scopus 로고
    • CFTR activation: Additive effects of stimulatory and inhibitory phosphorylation sites in the R domain
    • Wilkinson DJ, Strong TV, Mansoura MK, et al. CFTR activation: additive effects of stimulatory and inhibitory phosphorylation sites in the R domain. Am J Physiol Lung Cell Mol Physiol. 1997;273(1):L127-L133.
    • (1997) Am J Physiol Lung Cell Mol Physiol , vol.273 , Issue.1 , pp. L127-L133
    • Wilkinson, D.J.1    Strong, T.V.2    Mansoura, M.K.3
  • 21
    • 4143102419 scopus 로고    scopus 로고
    • Dibasic phosphorylation sites in the R domain of CFTR have stimulatory and inhibitory effects on channel activation
    • Vais H, Zhang R, Reenstra WW. Dibasic phosphorylation sites in the R domain of CFTR have stimulatory and inhibitory effects on channel activation. Am J Physiol Cell Physiol. 2004;287(3):C737-C745.
    • (2004) Am J Physiol Cell Physiol , vol.287 , Issue.3 , pp. C737-C745
    • Vais, H.1    Zhang, R.2    Reenstra, W.W.3
  • 22
    • 84888085224 scopus 로고    scopus 로고
    • Regulatory R region of the CFTR chloride channel is a dynamic integrator of phospho-dependent intra- and intermolecular interactions
    • Bozoky Z, Krzeminski M, Muhandiram R, et al. Regulatory R region of the CFTR chloride channel is a dynamic integrator of phospho-dependent intra- and intermolecular interactions. Proc Natl Acad Sci USA. 2013;110(47):E4427-E4436.
    • (2013) Proc Natl Acad Sci USA , vol.110 , Issue.47 , pp. E4427-E4436
    • Bozoky, Z.1    Krzeminski, M.2    Muhandiram, R.3
  • 23
    • 84883454123 scopus 로고    scopus 로고
    • Structural changes of CFTR R region upon phosphorylation: A plastic platform for intramolecular and intermolecular interactions
    • Bozoky Z, Krzeminski M, Chong PA, Forman-Kay JD. Structural changes of CFTR R region upon phosphorylation: a plastic platform for intramolecular and intermolecular interactions. FEBS J. 2013;280(18): 4407-4416.
    • (2013) FEBS J , vol.280 , Issue.18 , pp. 4407-4416
    • Bozoky, Z.1    Krzeminski, M.2    Chong, P.A.3    Forman-Kay, J.D.4
  • 25
    • 84901610851 scopus 로고    scopus 로고
    • On the structural organization of the intracellular domains of CFTR
    • Moran O. On the structural organization of the intracellular domains of CFTR. Int J Biochem Cell Biol. 2014;52:7-14.
    • (2014) Int J Biochem Cell Biol , vol.52 , pp. 7-14
    • Moran, O.1
  • 26
    • 65749102092 scopus 로고    scopus 로고
    • Gating of the CFTR Cl(−) channel by ATP-driven nucleotide-binding domain dimerisation
    • Hwang TC, Sheppard DN. Gating of the CFTR Cl(−) channel by ATP-driven nucleotide-binding domain dimerisation. J Physiol. 2009;587(pt 10):2151-2161.
    • (2009) J Physiol , vol.587 , pp. 2151-2161
    • Hwang, T.C.1    Sheppard, D.N.2
  • 27
    • 10744230777 scopus 로고    scopus 로고
    • Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator
    • Lewis HA, Buchanan SG, Burley SK, et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J. 2004;23(2):282-293.
    • (2004) EMBO J , vol.23 , Issue.2 , pp. 282-293
    • Lewis, H.A.1    Buchanan, S.G.2    Burley, S.K.3
  • 28
    • 14544300522 scopus 로고    scopus 로고
    • CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains
    • Vergani P, Lockless SW, Nairn AC, Gadsby DC. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature. 2005;433(7028):876-880.
    • (2005) Nature , vol.433 , Issue.7028 , pp. 876-880
    • Vergani, P.1    Lockless, S.W.2    Nairn, A.C.3    Gadsby, D.C.4
  • 29
    • 33749039521 scopus 로고    scopus 로고
    • The two ATP binding sites of cystic fibrosis transmembrane conductance regulator (CFTR) play distinct roles in gating kinetics and energetics
    • Zhou Z, Wang X, Liu HY, Zou X, Li M, Hwang TC. The two ATP binding sites of cystic fibrosis transmembrane conductance regulator (CFTR) play distinct roles in gating kinetics and energetics. J Gen Physiol. 2006;128(4):413-422.
    • (2006) J Gen Physiol , vol.128 , Issue.4 , pp. 413-422
    • Zhou, Z.1    Wang, X.2    Liu, H.Y.3    Zou, X.4    Li, M.5    Hwang, T.C.6
  • 30
    • 0025868103 scopus 로고
    • Demonstration that CFTR is a chloride channel by alteration of its anion selectivity
    • Anderson M, Gregory R, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science. 1991;253(5016):202-205.
    • (1991) Science , vol.253 , Issue.5016 , pp. 202-205
    • Anderson, M.1    Gregory, R.2    Thompson, S.3
  • 31
    • 32544435783 scopus 로고    scopus 로고
    • Mechanism of chloride permeation in the cystic fibrosis transmembrane conductance regulator chloride channel
    • Linsdell P. Mechanism of chloride permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. Exp Physiol. 2006;91(1):123-129.
    • (2006) Exp Physiol , vol.91 , Issue.1 , pp. 123-129
    • Linsdell, P.1
  • 32
    • 0031954021 scopus 로고    scopus 로고
    • Adenosine triphosphate-dependent asymmetry of anion permeation in the cystic fibrosis transmembrane conductance regulator chloride channel
    • Linsdell P, Hanrahan JW. Adenosine triphosphate-dependent asymmetry of anion permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. J Gen Physiol. 1998;111(4):601-614.
    • (1998) J Gen Physiol , vol.111 , Issue.4 , pp. 601-614
    • Linsdell, P.1    Hanrahan, J.W.2
  • 33
    • 84863395512 scopus 로고    scopus 로고
    • CFTR is the primary known apical glutathione transporter involved in cigarette smoke induced adaptive responses in the lung
    • Gould NS, Min E, Martin RJ, Day BJ. CFTR is the primary known apical glutathione transporter involved in cigarette smoke induced adaptive responses in the lung. Free Radic Biol Med. 2012;52(7):1201-1206.
    • (2012) Free Radic Biol Med , vol.52 , Issue.7 , pp. 1201-1206
    • Gould, N.S.1    Min, E.2    Martin, R.J.3    Day, B.J.4
  • 35
    • 60549083963 scopus 로고    scopus 로고
    • Mechanism of direct bicarbonate transport by the CFTR anion channel
    • Tang L, Fatehi M, Linsdell P. Mechanism of direct bicarbonate transport by the CFTR anion channel. J Cyst Fibros. 2009;8(2):115-121.
    • (2009) J Cyst Fibros , vol.8 , Issue.2 , pp. 115-121
    • Tang, L.1    Fatehi, M.2    Linsdell, P.3
  • 36
    • 0020700816 scopus 로고
    • Chloride impermeability in cystic fibrosis
    • Quinton PM. Chloride impermeability in cystic fibrosis. Nature. 1983;301(5899):421-422.
    • (1983) Nature , vol.301 , Issue.5899 , pp. 421-422
    • Quinton, P.M.1
  • 37
    • 48149090717 scopus 로고    scopus 로고
    • Cystic fibrosis: Impaired bicarbonate secretion and mucoviscidosis
    • Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008;372(9636):415-417.
    • (2008) Lancet , vol.372 , Issue.9636 , pp. 415-417
    • Quinton, P.M.1
  • 38
    • 0019809960 scopus 로고
    • Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis
    • Knowles M, Gatzy J, Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med. 1981;305(25):1489-1495.
    • (1981) N Engl J Med , vol.305 , Issue.25 , pp. 1489-1495
    • Knowles, M.1    Gatzy, J.2    Boucher, R.3
  • 39
    • 84942123413 scopus 로고    scopus 로고
    • Targeting ENaC as a molecular suspect in cystic fibrosis
    • Bangel-Ruland N, Tomczak K, Weber WM. Targeting ENaC as a molecular suspect in cystic fibrosis. Curr Drug Targets. 2015;16(9):951-957.
    • (2015) Curr Drug Targets , vol.16 , Issue.9 , pp. 951-957
    • Bangel-Ruland, N.1    Tomczak, K.2    Weber, W.M.3
  • 40
    • 0032433707 scopus 로고    scopus 로고
    • Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease
    • Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95(7):1005-1015.
    • (1998) Cell , vol.95 , Issue.7 , pp. 1005-1015
    • Matsui, H.1    Grubb, B.R.2    Tarran, R.3
  • 42
    • 84884284486 scopus 로고    scopus 로고
    • Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease?
    • Hobbs CA, Da Tan C, Tarran R. Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease? J Physiol. 2013;591(pt 18):4377-4387.
    • (2013) J Physiol , vol.591 , pp. 4377-4387
    • Hobbs, C.A.1    Da Tan, C.2    Tarran, R.3
  • 43
    • 37549035927 scopus 로고    scopus 로고
    • Molecular proximity of cystic fibrosis transmembrane conductance regulator and epithelial sodium channel assessed by fluorescence resonance energy transfer
    • Berdiev BK, Cormet-Boyaka E, Tousson A, et al. Molecular proximity of cystic fibrosis transmembrane conductance regulator and epithelial sodium channel assessed by fluorescence resonance energy transfer. J Biol Chem. 2007;282(50):36481-36488.
    • (2007) J Biol Chem , vol.282 , Issue.50 , pp. 36481-36488
    • Berdiev, B.K.1    Cormet-Boyaka, E.2    Tousson, A.3
  • 44
    • 0034623128 scopus 로고    scopus 로고
    • The cytosolic termini of the β- and γ- ENaC subunits are involved in the functional interactions between CFTR and ENaC
    • Ji HL, Chalfant ML, Jovov B, et al. The cytosolic termini of the β- and γ- ENaC subunits are involved in the functional interactions between CFTR and ENaC. J Biol Chem. 2000;275(36):27947-27956.
    • (2000) J Biol Chem , vol.275 , Issue.36 , pp. 27947-27956
    • Ji, H.L.1    Chalfant, M.L.2    Jovov, B.3
  • 45
    • 0031024767 scopus 로고    scopus 로고
    • Inhibition of epithelial Na+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator
    • Kunzelmann K, Kiser GL, Schreiber R, Riordan JR. Inhibition of epithelial Na+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator. FEBS Lett. 1997;400(3):341-344.
    • (1997) FEBS Lett , vol.400 , Issue.3 , pp. 341-344
    • Kunzelmann, K.1    Kiser, G.L.2    Schreiber, R.3    Riordan, J.R.4
  • 46
    • 0037283010 scopus 로고    scopus 로고
    • CAMP-dependent activation of CFTR inhibits the epithelial sodium channel (ENaC) without affecting its surface expression
    • Konstas AA, Koch JP, Korbmacher C. cAMP-dependent activation of CFTR inhibits the epithelial sodium channel (ENaC) without affecting its surface expression. Pflügers Arch. 2003;445(4):513-521.
    • (2003) Pflügers Arch , vol.445 , Issue.4 , pp. 513-521
    • Konstas, A.A.1    Koch, J.P.2    Korbmacher, C.3
  • 47
    • 0028276637 scopus 로고
    • Mechanism of sodium hyperabsorption in cultured cystic fibrosis nasal epithelium: A patch-clamp study
    • Chinet TC, Fullton JM, Yankaskas JR, Boucher RC, Stutts MJ. Mechanism of sodium hyperabsorption in cultured cystic fibrosis nasal epithelium: a patch-clamp study. Am J Physiol Cell Physiol. 1994;266(4):C1061-C1068.
    • (1994) Am J Physiol Cell Physiol , vol.266 , Issue.4 , pp. C1061-C1068
    • Chinet, T.C.1    Fullton, J.M.2    Yankaskas, J.R.3    Boucher, R.C.4    Stutts, M.J.5
  • 48
    • 77957767326 scopus 로고    scopus 로고
    • The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na(+) channel
    • Gentzsch M, Dang H, Dang Y, et al. The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na(+) channel. J Biol Chem. 2010;285(42):32227-32232.
    • (2010) J Biol Chem , vol.285 , Issue.42 , pp. 32227-32232
    • Gentzsch, M.1    Dang, H.2    Dang, Y.3
  • 49
    • 35648949295 scopus 로고    scopus 로고
    • CFTR stabilizes ENaC at the plasma membrane
    • Lu C, Jiang C, Pribanic S, Rotin D. CFTR stabilizes ENaC at the plasma membrane. J Cyst Fibros. 2007;6(6):419-422.
    • (2007) J Cyst Fibros , vol.6 , Issue.6 , pp. 419-422
    • Lu, C.1    Jiang, C.2    Pribanic, S.3    Rotin, D.4
  • 50
    • 0037274990 scopus 로고    scopus 로고
    • ENaC-CFTR interactions: The role of electrical coupling of ion fluxes explored in an epithelial cell model
    • Horisberger J-D. ENaC-CFTR interactions: the role of electrical coupling of ion fluxes explored in an epithelial cell model. Pflügers Arch. 2003;445(4):522-528.
    • (2003) Pflügers Arch , vol.445 , Issue.4 , pp. 522-528
    • Horisberger, J.-D.1
  • 52
    • 84864521244 scopus 로고    scopus 로고
    • Airway epithelial cells - Functional links between CFTR and anoctamin dependent Cl− secretion
    • Kunzelmann K, Tian Y, Martins JR, et al. Airway epithelial cells - functional links between CFTR and anoctamin dependent Cl− secretion. Int J Biochem Cell Biol. 2012;44(11):1897-1900.
    • (2012) Int J Biochem Cell Biol , vol.44 , Issue.11 , pp. 1897-1900
    • Kunzelmann, K.1    Tian, Y.2    Martins, J.R.3
  • 53
    • 84901635712 scopus 로고    scopus 로고
    • Functional interaction of the cystic fibrosis transmembrane conductance regulator with members of the SLC26 family of anion transporters (SLC26A8 and SLC26A9): Physiological and pathophysiological relevance
    • El Khouri E, Touré A. Functional interaction of the cystic fibrosis transmembrane conductance regulator with members of the SLC26 family of anion transporters (SLC26A8 and SLC26A9): physiological and pathophysiological relevance. Int J Biochem Cell Biol. 2014;52:58-67.
    • (2014) Int J Biochem Cell Biol , vol.52 , pp. 58-67
    • El Khouri, E.1    Touré, A.2
  • 54
    • 51149118485 scopus 로고    scopus 로고
    • Characterization of SLC26A9, facilitation of Cl- transport by bicarbonate
    • Loriol C, Dulong S, Avella M, et al. Characterization of SLC26A9, facilitation of Cl- transport by bicarbonate. Cell Physiol Biochem. 2008;22(1-4):015-030.
    • (2008) Cell Physiol Biochem , vol.22 , Issue.1-4 , pp. 015-030
    • Loriol, C.1    Dulong, S.2    Avella, M.3
  • 55
    • 64549085967 scopus 로고    scopus 로고
    • SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia
    • Bertrand CA, Zhang R, Pilewski JM, Frizzell RA. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J Gen Physiol. 2009;133(4):421-438.
    • (2009) J Gen Physiol , vol.133 , Issue.4 , pp. 421-438
    • Bertrand, C.A.1    Zhang, R.2    Pilewski, J.M.3    Frizzell, R.A.4
  • 56
    • 84857478183 scopus 로고    scopus 로고
    • Differential contribution of SLC26A9 to Cl− conductance in polarized and non-polarized epithelial cells
    • Ousingsawat J, Schreiber R, Kunzelmann K. Differential contribution of SLC26A9 to Cl− conductance in polarized and non-polarized epithelial cells. J Gen Physiol. 2012;227(6):2323-2329.
    • (2012) J Gen Physiol , vol.227 , Issue.6 , pp. 2323-2329
    • Ousingsawat, J.1    Schreiber, R.2    Kunzelmann, K.3
  • 57
    • 0033618404 scopus 로고    scopus 로고
    • C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis: A novel class of mutation
    • Haardt M, Benharouga M, Lechardeur D, Kartner N, Lukacs GL. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis: a novel class of mutation. J Biol Chem. 1999;274(31):21873-21877.
    • (1999) J Biol Chem , vol.274 , Issue.31 , pp. 21873-21877
    • Haardt, M.1    Benharouga, M.2    Lechardeur, D.3    Kartner, N.4    Lukacs, G.L.5
  • 58
    • 0027162649 scopus 로고
    • Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
    • Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73(7):1251-1254.
    • (1993) Cell , vol.73 , Issue.7 , pp. 1251-1254
    • Welsh, M.J.1    Smith, A.E.2
  • 59
    • 22044440151 scopus 로고    scopus 로고
    • Mutation spectrum in Jewish cystic fibrosis patients in Israel: Implication to carrier screening
    • Quint A, Lerer I, Sagi M, Abeliovich D. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. Am J Med Genet A. 2005;136A(3):246-248.
    • (2005) Am J Med Genet A , vol.136A , Issue.3 , pp. 246-248
    • Quint, A.1    Lerer, I.2    Sagi, M.3    Abeliovich, D.4
  • 60
    • 0025242929 scopus 로고
    • Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
    • Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 1990;63(4):827-834.
    • (1990) Cell , vol.63 , Issue.4 , pp. 827-834
    • Cheng, S.H.1    Gregory, R.J.2    Marshall, J.3
  • 61
    • 0026781952 scopus 로고
    • Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
    • Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 1992;358(6389):761-764.
    • (1992) Nature , vol.358 , Issue.6389 , pp. 761-764
    • Denning, G.M.1    Erson, M.P.2    Amara, J.F.3    Marshall, J.4    Smith, A.E.5    Welsh, M.J.6
  • 62
    • 0036258208 scopus 로고    scopus 로고
    • Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening
    • Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575-606.
    • (2002) Hum Mutat , vol.19 , Issue.6 , pp. 575-606
    • Bobadilla, J.L.1    Macek, M.2    Fine, J.P.3    Farrell, P.M.4
  • 63
    • 0026325533 scopus 로고
    • Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation
    • Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation. Nature. 1991;354(6354):526-528.
    • (1991) Nature , vol.354 , Issue.6354 , pp. 526-528
    • Dalemans, W.1    Barbry, P.2    Champigny, G.3
  • 64
    • 41149113942 scopus 로고    scopus 로고
    • Enhanced cell surface stability of rescued ΔF508 cystic fibrosis transmembrane conductance regulator by pharmacological chaperones
    • Varga K, Goldstein RF, Jurkuvenaite A, et al. Enhanced cell surface stability of rescued ΔF508 cystic fibrosis transmembrane conductance regulator by pharmacological chaperones. Biochem J. 2008;410(3):555-564.
    • (2008) Biochem J , vol.410 , Issue.3 , pp. 555-564
    • Varga, K.1    Goldstein, R.F.2    Jurkuvenaite, A.3
  • 65
    • 84992067869 scopus 로고    scopus 로고
    • Natural compounds as therapeutic agents in the treatment cystic fibrosis
    • Dey I, Shah K, Bradbury NA. Natural compounds as therapeutic agents in the treatment cystic fibrosis. J Genet Syndr Gene Ther. 2016;7(1):284.
    • (2016) J Genet Syndr Gene Ther , vol.7 , Issue.1 , pp. 284
    • Dey, I.1    Shah, K.2    Bradbury, N.A.3
  • 66
    • 0026337305 scopus 로고
    • Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes
    • Drumm M, Wilkinson D, Smit L, et al. Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science. 1991;254(5039):1797-1799.
    • (1991) Science , vol.254 , Issue.5039 , pp. 1797-1799
    • Drumm, M.1    Wilkinson, D.2    Smit, L.3
  • 67
    • 0028577602 scopus 로고
    • Phosphatase inhibitors activate normal and defective CFTR chloride channels
    • Becq F, Jensen TJ, Chang XB, et al. Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc Natl Acad Sci USA. 1994;91(19):9160-9164.
    • (1994) Proc Natl Acad Sci USA , vol.91 , Issue.19 , pp. 9160-9164
    • Becq, F.1    Jensen, T.J.2    Chang, X.B.3
  • 68
    • 0027220387 scopus 로고
    • Possible regulation of CFTR-chloride channels by membrane-bound phosphatases in pancreatic duct cells
    • Becq F, Fanjul M, Merten M, Figarella C, Hollande E, Gola M. Possible regulation of CFTR-chloride channels by membrane-bound phosphatases in pancreatic duct cells. FEBS Lett. 1993;327(3):337-342.
    • (1993) FEBS Lett , vol.327 , Issue.3 , pp. 337-342
    • Becq, F.1    Fanjul, M.2    Merten, M.3    Figarella, C.4    Hollande, E.5    Gola, M.6
  • 69
    • 0031990988 scopus 로고    scopus 로고
    • Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel
    • Chappe V, Mettey Y, Vierfond JM, et al. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Br J Pharmacol. 1998;123(4):683-693.
    • (1998) Br J Pharmacol , vol.123 , Issue.4 , pp. 683-693
    • Chappe, V.1    Mettey, Y.2    Vierfond, J.M.3
  • 70
    • 0030943895 scopus 로고    scopus 로고
    • 8-Cyclopentyl-1,3-dipropylx-anthine and other xanthines differentially bind to the wild-type and ΔF508 mutant first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator
    • Cohen BE, Lee G, Jacobson KA, et al. 8-Cyclopentyl-1,3-dipropylx-anthine and other xanthines differentially bind to the wild-type and ΔF508 mutant first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry. 1997;36(21):6455-6461.
    • (1997) Biochemistry , vol.36 , Issue.21 , pp. 6455-6461
    • Cohen, B.E.1    Lee, G.2    Jacobson, K.A.3
  • 71
    • 0031763141 scopus 로고    scopus 로고
    • Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo
    • Illek B, Fischer H. Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 1998;275(5):L902-L910.
    • (1998) Am J Physiol Lung Cell Mol Physiol , vol.275 , Issue.5 , pp. L902-L910
    • Illek, B.1    Fischer, H.2
  • 72
    • 0030850643 scopus 로고    scopus 로고
    • Genistein activates CFTR Cl- channels via a tyrosine kinase- and protein phosphatase-independent mechanism
    • French PJ, Bijman J, Bot AG, Boomaars WE, Scholte BJ, de Jonge HR. Genistein activates CFTR Cl- channels via a tyrosine kinase- and protein phosphatase-independent mechanism. Am J Physiol Cell Physiol. 1997;273(2):C747-C753.
    • (1997) Am J Physiol Cell Physiol , vol.273 , Issue.2 , pp. C747-C753
    • French, P.J.1    Bijman, J.2    Bot, A.G.3    Boomaars, W.E.4    Scholte, B.J.5    De Jonge, H.R.6
  • 74
    • 0030773897 scopus 로고    scopus 로고
    • Genistein potentiates wild-type and delta F508-CFTR channel activity
    • Hwang TC, Wang F, Yang IC, Reenstra WW. Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol. 1997;273(3 pt 1):C988-C998.
    • (1997) Am J Physiol , vol.273 , Issue.3 , pp. C988-C998
    • Hwang, T.C.1    Wang, F.2    Yang, I.C.3    Reenstra, W.W.4
  • 75
    • 0032743305 scopus 로고    scopus 로고
    • Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein
    • Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol Cell Physiol. 1999;277(4): C833-C839.
    • (1999) Am J Physiol Cell Physiol , vol.277 , Issue.4 , pp. C833-C839
    • Illek, B.1    Zhang, L.2    Lewis, N.C.3    Moss, R.B.4    Dong, J.Y.5    Fischer, H.6
  • 76
    • 15044353957 scopus 로고    scopus 로고
    • Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains
    • Moran O, Galietta LJV, Zegarra-Moran O. Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci. 2005;62(4):446-460.
    • (2005) Cell Mol Life Sci , vol.62 , Issue.4 , pp. 446-460
    • Moran, O.1    Galietta, L.2    Zegarra-Moran, O.3
  • 77
    • 33947543364 scopus 로고    scopus 로고
    • Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains
    • Wang W, Bernard K, Li G, Kirk KL. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem. 2007;282(7):4533-4544.
    • (2007) J Biol Chem , vol.282 , Issue.7 , pp. 4533-4544
    • Wang, W.1    Bernard, K.2    Li, G.3    Kirk, K.L.4
  • 78
    • 0036115199 scopus 로고    scopus 로고
    • Calcium-pump inhibitors induce functional surface expression of delF508-CFTR protein in cystic fibrosis epithelial cells
    • Egan ME, Glockner-Pagel J, Ambrose CA, et al. Calcium-pump inhibitors induce functional surface expression of delF508-CFTR protein in cystic fibrosis epithelial cells. Nat Med. 2002;8(5):485-492.
    • (2002) Nat Med , vol.8 , Issue.5 , pp. 485-492
    • Egan, M.E.1    Glockner-Pagel, J.2    Ambrose, C.A.3
  • 79
    • 33645235405 scopus 로고    scopus 로고
    • Maintaining low Ca2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells
    • Norez C, Antigny F, Becq F, Vandebrouck C. Maintaining low Ca2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. Traffic. 2006;7(5): 562-573.
    • (2006) Traffic , vol.7 , Issue.5 , pp. 562-573
    • Norez, C.1    Antigny, F.2    Becq, F.3    Vandebrouck, C.4
  • 80
    • 11144355340 scopus 로고    scopus 로고
    • Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects
    • Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004;304(5670): 600-602.
    • (2004) Science , vol.304 , Issue.5670 , pp. 600-602
    • Egan, M.E.1    Pearson, M.2    Weiner, S.A.3
  • 81
    • 4644360693 scopus 로고    scopus 로고
    • Evidence against the rescue of defective ΔF508-CFTR cellular processing by curcumin in cell culture and mouse models
    • Song Y, Sonawane ND, Salinas D, et al. Evidence against the rescue of defective ΔF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem. 2004;279(39):40629-40633.
    • (2004) J Biol Chem , vol.279 , Issue.39 , pp. 40629-40633
    • Song, Y.1    Sonawane, N.D.2    Salinas, D.3
  • 82
    • 33644625310 scopus 로고    scopus 로고
    • SERCA pump inhibitors do not correct biosynthetic arrest of ΔF508 CFTR in cystic fibrosis
    • Grubb BR, Gabriel SE, Mengos A, et al. SERCA pump inhibitors do not correct biosynthetic arrest of ΔF508 CFTR in cystic fibrosis. Am J Respir Cell Mol Biol. 2006;34(3):355-363.
    • (2006) Am J Respir Cell Mol Biol , vol.34 , Issue.3 , pp. 355-363
    • Grubb, B.R.1    Gabriel, S.E.2    Mengos, A.3
  • 83
    • 84884732389 scopus 로고    scopus 로고
    • CFTR chloride channel is a molecular target of the natural cancer preventive agent resveratrol
    • Yang S, Yu B, Sui Y, et al. CFTR chloride channel is a molecular target of the natural cancer preventive agent resveratrol. Pharmazie. 2013;68(9):772-776.
    • (2013) Pharmazie , vol.68 , Issue.9 , pp. 772-776
    • Yang, S.1    Yu, B.2    Sui, Y.3
  • 84
    • 0033636431 scopus 로고    scopus 로고
    • Structural determinants for activation and block of CFTR-mediated chloride currents by apigenin
    • Illek B, Lizarzaburu ME, Lee V, Nantz MH, Kurth MJ, Fischer H. Structural determinants for activation and block of CFTR-mediated chloride currents by apigenin. Am J Physiol Cell Physiol. 2000; 279(6):C1838-C1846.
    • (2000) Am J Physiol Cell Physiol , vol.279 , Issue.6 , pp. C1838-C1846
    • Illek, B.1    Lizarzaburu, M.E.2    Lee, V.3    Nantz, M.H.4    Kurth, M.J.5    Fischer, H.6
  • 85
    • 79958270724 scopus 로고    scopus 로고
    • Resveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epithelium
    • Alexander NS, Hatch N, Zhang S, et al. Resveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epithelium. Laryngoscope. 2011;121(6):1313-1319.
    • (2011) Laryngoscope , vol.121 , Issue.6 , pp. 1313-1319
    • Alexander, N.S.1    Hatch, N.2    Zhang, S.3
  • 86
    • 84979769205 scopus 로고    scopus 로고
    • Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice
    • Dhooghe B, Bouckaert C, Capron A, Wallemacq P, Leal T, Noel S. Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice. Biol Open. 2015;4(7):929-936.
    • (2015) Biol Open , vol.4 , Issue.7 , pp. 929-936
    • Dhooghe, B.1    Bouckaert, C.2    Capron, A.3    Wallemacq, P.4    Leal, T.5    Noel, S.6
  • 87
    • 84942191864 scopus 로고    scopus 로고
    • Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-induced model of acquired CFTR deficiency
    • Woodworth BA. Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-induced model of acquired CFTR deficiency. Laryngoscope. 2015;125(suppl 7):S1-S13.
    • (2015) Laryngoscope , vol.125 , pp. SS1-S13
    • Woodworth, B.A.1
  • 88
    • 79958046677 scopus 로고    scopus 로고
    • Resveratrol rescues cAMP-dependent anionic transport in the cystic fibrosis pancreatic cell line CFPAC1
    • Hamdaoui N, Baudoin-Legros M, Kelly M, et al. Resveratrol rescues cAMP-dependent anionic transport in the cystic fibrosis pancreatic cell line CFPAC1. Br J Pharmacol. 2011;163(4):876-886.
    • (2011) Br J Pharmacol , vol.163 , Issue.4 , pp. 876-886
    • Hamdaoui, N.1    Baudoin-Legros, M.2    Kelly, M.3
  • 89
    • 84941595661 scopus 로고    scopus 로고
    • Evidence against resveratrol as a viable therapy for the rescue of defective ΔF508 CFTR
    • Jai Y, Shah K, Bridges RJ, Bradbury NA. Evidence against resveratrol as a viable therapy for the rescue of defective ΔF508 CFTR. Biochim Biophys Acta. 2015;1850(11):2377-2384.
    • (2015) Biochim Biophys Acta , vol.1850 , Issue.11 , pp. 2377-2384
    • Jai, Y.1    Shah, K.2    Bridges, R.J.3    Bradbury, N.A.4
  • 90
  • 91
    • 0037180511 scopus 로고    scopus 로고
    • Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease
    • Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA. 2002;99(24):15428-15433.
    • (2002) Proc Natl Acad Sci USA , vol.99 , Issue.24 , pp. 15428-15433
    • Sawkar, A.R.1    Cheng, W.C.2    Beutler, E.3    Wong, C.H.4    Balch, W.E.5    Kelly, J.W.6
  • 92
    • 44249097535 scopus 로고    scopus 로고
    • Parallel improvement of sodium and chloride transport defects by miglustat (N-butyl-deoxynojyrimicin) in cystic fibrosis epithelial cells
    • Noël S, Wilke M, Bot AGM, De Jonge HR, Becq F. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyl-deoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther. 2008;325(3):1016-1023.
    • (2008) J Pharmacol Exp Ther , vol.325 , Issue.3 , pp. 1016-1023
    • Noël, S.1    Wilke, M.2    Bot, A.3    De Jonge, H.R.4    Becq, F.5
  • 93
    • 33645211759 scopus 로고    scopus 로고
    • Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the α-glucosidase inhibitor miglustat
    • Norez C, Noel S, Wilke M, et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the α-glucosidase inhibitor miglustat. FEBS Lett. 2006;580(8):2081-2086.
    • (2006) FEBS Lett , vol.580 , Issue.8 , pp. 2081-2086
    • Norez, C.1    Noel, S.2    Wilke, M.3
  • 94
    • 66249120003 scopus 로고    scopus 로고
    • Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice
    • Lubamba B, Lebacq J, Lebecque P, et al. Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med. 2009;179(11): 1022-1028.
    • (2009) Am J Respir Crit Care Med , vol.179 , Issue.11 , pp. 1022-1028
    • Lubamba, B.1    Lebacq, J.2    Lebecque, P.3
  • 95
    • 84860605804 scopus 로고    scopus 로고
    • Randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference
    • Leonard A, Lebecque P, Dingemanse J, Leal T. A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros. 2012;11(3):231-236.
    • (2012) J Cyst Fibros , vol.11 , Issue.3 , pp. 231-236
    • Leonard, A.1    Lebecque, P.2    Dingemanse, J.3    Leal, T.A.4
  • 97
    • 84949085676 scopus 로고    scopus 로고
    • Riociguat for the treatment of pulmonary hypertension
    • Hambly N, Granton J. Riociguat for the treatment of pulmonary hypertension. Expert Rev Respir Med. 2015;9(6):679-695.
    • (2015) Expert Rev Respir Med , vol.9 , Issue.6 , pp. 679-695
    • Hambly, N.1    Granton, J.2
  • 98
    • 84861354967 scopus 로고    scopus 로고
    • Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease
    • Leier G, Bangel-Ruland N, Sobczak K, Knieper Y, Weber WM. Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease. Cell Physiol Biochem. 2012;29(5-6):775-790.
    • (2012) Cell Physiol Biochem , vol.29 , Issue.5-6 , pp. 775-790
    • Leier, G.1    Bangel-Ruland, N.2    Sobczak, K.3    Knieper, Y.4    Weber, W.M.5
  • 99
    • 11944265976 scopus 로고    scopus 로고
    • Sildenafil (Viagra) corrects ΔF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis
    • Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects ΔF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax. 2005;60(1):55-59.
    • (2005) Thorax , vol.60 , Issue.1 , pp. 55-59
    • Dormer, R.L.1    Harris, C.M.2    Clark, Z.3
  • 100
    • 84886248189 scopus 로고    scopus 로고
    • Correction of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis mice
    • Dhooghe B, Noël S, Bouzin C, Behets-Wydemans G, Leal T. Correction of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis mice. PLoS One. 2013;8(10):e77314.
    • (2013) Plos One , vol.8 , Issue.10
    • Dhooghe, B.1    Noël, S.2    Bouzin, C.3    Behets-Wydemans, G.4    Leal, T.5
  • 101
    • 40649117683 scopus 로고    scopus 로고
    • Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis
    • Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med. 2008;177(5):506-515.
    • (2008) Am J Respir Crit Care Med , vol.177 , Issue.5 , pp. 506-515
    • Lubamba, B.1    Lecourt, H.2    Lebacq, J.3
  • 102
    • 84924257957 scopus 로고    scopus 로고
    • Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease
    • Taylor-Cousar JL, Wiley C, Felton LA, et al. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. J Cyst Fibros. 2015;14(2):228-236.
    • (2015) J Cyst Fibros , vol.14 , Issue.2 , pp. 228-236
    • Taylor-Cousar, J.L.1    Wiley, C.2    Felton, L.A.3
  • 103
    • 84880721470 scopus 로고    scopus 로고
    • Riociguat for the treatment of pulmonary arterial hypertension
    • Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4): 330-340.
    • (2013) N Engl J Med , vol.369 , Issue.4 , pp. 330-340
    • Ghofrani, H.A.1    Galiè, N.2    Grimminger, F.3
  • 104
    • 67651094166 scopus 로고    scopus 로고
    • Discovery of riociguat (BAY 63-2521): A potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
    • Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem. 2009;4(5):853-865.
    • (2009) Chemmedchem , vol.4 , Issue.5 , pp. 853-865
    • Mittendorf, J.1    Weigand, S.2    Alonso-Alija, C.3
  • 105
    • 36848999782 scopus 로고    scopus 로고
    • Clinical use of ibuprofen is associated with slower FEV(1) decline in children with cystic fibrosis
    • Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of ibuprofen is associated with slower FEV(1) decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2007;176(11): 1084-1089.
    • (2007) Am J Respir Crit Care Med , vol.176 , Issue.11 , pp. 1084-1089
    • Konstan, M.W.1    Schluchter, M.D.2    Xue, W.3    Davis, P.B.4
  • 106
    • 84918785468 scopus 로고    scopus 로고
    • Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking
    • Carlile GW, Robert R, Goepp J, et al. Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking. J Cyst Fibros. 2015;14(1):16-25.
    • (2015) J Cyst Fibros , vol.14 , Issue.1 , pp. 16-25
    • Carlile, G.W.1    Robert, R.2    Goepp, J.3
  • 107
    • 0347320495 scopus 로고    scopus 로고
    • Early oral cysteamine therapy for nephropathic cystinosis
    • Gahl WA. Early oral cysteamine therapy for nephropathic cystinosis. Eur J Pediatr. 2003;162(1):S38-S41.
    • (2003) Eur J Pediatr , vol.162 , Issue.1 , pp. S38-S41
    • Gahl, W.A.1
  • 108
    • 77956396747 scopus 로고    scopus 로고
    • Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition
    • Luciani A, Villella VR, Esposito S, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol. 2010;12(9):863-875.
    • (2010) Nat Cell Biol , vol.12 , Issue.9 , pp. 863-875
    • Luciani, A.1    Villella, V.R.2    Esposito, S.3
  • 109
    • 80655134731 scopus 로고    scopus 로고
    • Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis
    • Abdulrahman BA, Khweek AA, Akhter A, et al. Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy. 2011;7(11):1359-1370.
    • (2011) Autophagy , vol.7 , Issue.11 , pp. 1359-1370
    • Abdulrahman, B.A.1    Khweek, A.A.2    Akhter, A.3
  • 110
    • 84869389296 scopus 로고    scopus 로고
    • Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator
    • Luciani A, Villella VR, Esposito S, et al. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator. Autophagy. 2012;8(11):1657-1672.
    • (2012) Autophagy , vol.8 , Issue.11 , pp. 1657-1672
    • Luciani, A.1    Villella, V.R.2    Esposito, S.3
  • 111
    • 84919764939 scopus 로고    scopus 로고
    • Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
    • Stefano DD, Villella VR, Esposito S, et al. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy. 2014;10(11):2053-2074.
    • (2014) Autophagy , vol.10 , Issue.11 , pp. 2053-2074
    • Stefano, D.D.1    Villella, V.R.2    Esposito, S.3
  • 112
    • 84962121102 scopus 로고    scopus 로고
    • A novel treatment of cystic fibrosis acting on-target: Cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR
    • Epub, Jul 22
    • Tosco A, De Gregorio F, Esposito S, et al. A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ. Epub 2016 Jul 22.
    • (2016) Cell Death Differ
    • Tosco, A.1    De Gregorio, F.2    Esposito, S.3
  • 113
    • 0034828555 scopus 로고    scopus 로고
    • Aescin: Pharmacology, pharmacokinetics and therapeutic profile
    • Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44(3):183-193.
    • (2001) Pharmacol Res , vol.44 , Issue.3 , pp. 183-193
    • Sirtori, C.R.1
  • 114
    • 84969178328 scopus 로고    scopus 로고
    • Discovery of clinically approved agents that promote suppression of CFTR nonsense mutations
    • Apr 22
    • Mutyam V, Du M, Xue X, et al. Discovery of clinically approved agents that promote suppression of CFTR nonsense mutations. Am J Respir Crit Care Med. Epub 2016 Apr 22.
    • (2016) Am J Respir Crit Care Med. Epub
    • Mutyam, V.1    Du, M.2    Xue, X.3
  • 115
    • 0037020097 scopus 로고    scopus 로고
    • High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening
    • Ma T, Vetrivel L, Yang H, et al. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem. 2002;277(40):37235-37241.
    • (2002) J Biol Chem , vol.277 , Issue.40 , pp. 37235-37241
    • Ma, T.1    Vetrivel, L.2    Yang, H.3
  • 116
    • 24644464284 scopus 로고    scopus 로고
    • Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening
    • Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest. 2005;115(9):2564-2571.
    • (2005) J Clin Invest , vol.115 , Issue.9 , pp. 2564-2571
    • Pedemonte, N.1    Lukacs, G.L.2    Du, K.3
  • 117
    • 33744831154 scopus 로고    scopus 로고
    • Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules
    • Van Goor F, Straley KS, Cao D, et al. Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol. 2006;290(6): L1117-L1130.
    • (2006) Am J Physiol Lung Cell Mol Physiol , vol.290 , Issue.6 , pp. L1117-L1130
    • Van Goor, F.1    Straley, K.S.2    Cao, D.3
  • 118
    • 34247200483 scopus 로고    scopus 로고
    • Vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: A pilot study
    • Sermet-Gaudelus I, Renouil M, Fajac A, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med. 2007;5:5-5.
    • (2007) BMC Med , vol.5
    • Sermet-Gaudelus, I.1    Renouil, M.2    Fajac, A.3
  • 119
    • 0029994529 scopus 로고    scopus 로고
    • Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations
    • Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med. 1996;2(4):467-469.
    • (1996) Nat Med , vol.2 , Issue.4 , pp. 467-469
    • Howard, M.1    Frizzell, R.A.2    Bedwell, D.M.3
  • 120
    • 0030702773 scopus 로고    scopus 로고
    • Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line
    • Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med. 1997;3(11):1280-1284.
    • (1997) Nat Med , vol.3 , Issue.11 , pp. 1280-1284
    • Bedwell, D.M.1    Kaenjak, A.2    Benos, D.J.3
  • 121
    • 0141863491 scopus 로고    scopus 로고
    • Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations
    • Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349(15):1433-1441.
    • (2003) N Engl J Med , vol.349 , Issue.15 , pp. 1433-1441
    • Wilschanski, M.1    Yahav, Y.2    Yaacov, Y.3
  • 122
    • 0034073736 scopus 로고    scopus 로고
    • A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations
    • Wilschanski M, Famini C, Blau H, et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med. 2000;161(3):860-865.
    • (2000) Am J Respir Crit Care Med , vol.161 , Issue.3 , pp. 860-865
    • Wilschanski, M.1    Famini, C.2    Blau, H.3
  • 123
    • 0034961464 scopus 로고    scopus 로고
    • Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis
    • Clancy JP, Bebök Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001;163(7):1683-1692.
    • (2001) Am J Respir Crit Care Med , vol.163 , Issue.7 , pp. 1683-1692
    • Clancy, J.P.1    Bebök, Z.2    Ruiz, F.3
  • 124
    • 34347224756 scopus 로고    scopus 로고
    • No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations
    • Clancy JP, Rowe SM, Bebok Z, et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol. 2007;37(1):57-66.
    • (2007) Am J Respir Cell Mol Biol , vol.37 , Issue.1 , pp. 57-66
    • Clancy, J.P.1    Rowe, S.M.2    Bebok, Z.3
  • 125
    • 65649136885 scopus 로고    scopus 로고
    • Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations
    • Nudelman I, Rebibo-Sabbah A, Cherniavsky M, et al. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem. 2009;52(9):2836-2845.
    • (2009) J Med Chem , vol.52 , Issue.9 , pp. 2836-2845
    • Nudelman, I.1    Rebibo-Sabbah, A.2    Cherniavsky, M.3
  • 126
    • 84965035945 scopus 로고    scopus 로고
    • Design of novel aminoglycoside derivatives with enhanced suppression of diseases-causing nonsense mutations
    • Sabbavarapu NM, Shavit M, Degani Y, Smolkin B, Belakhov V, Baasov T. Design of novel aminoglycoside derivatives with enhanced suppression of diseases-causing nonsense mutations. ACS Med Chem Lett. 2016;7(4):418-423.
    • (2016) ACS Med Chem Lett , vol.7 , Issue.4 , pp. 418-423
    • Sabbavarapu, N.M.1    Shavit, M.2    Degani, Y.3    Smolkin, B.4    Belakhov, V.5    Baasov, T.6
  • 127
    • 84898715557 scopus 로고    scopus 로고
    • Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor
    • Xue X, Mutyam V, Tang L, et al. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol. 2014;50(4):805-816.
    • (2014) Am J Respir Cell Mol Biol , vol.50 , Issue.4 , pp. 805-816
    • Xue, X.1    Mutyam, V.2    Tang, L.3
  • 128
    • 80755133472 scopus 로고    scopus 로고
    • Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54
    • Rowe SM, Sloane P, Tang LP, et al. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J Mol Med (Berl). 2011;89(11): 1149-1161.
    • (2011) J Mol Med (Berl) , vol.89 , Issue.11 , pp. 1149-1161
    • Rowe, S.M.1    Sloane, P.2    Tang, L.P.3
  • 129
    • 0036379141 scopus 로고    scopus 로고
    • -/- mouse carrying a human CFTR-G542X transgene
    • -/- mouse carrying a human CFTR-G542X transgene. J Mol Med (Berl). 2002;80(9):595-604.
    • (2002) J Mol Med (Berl) , vol.80 , Issue.9 , pp. 595-604
    • Du, M.1    Jones, J.R.2    Lanier, J.3
  • 130
    • 33751064254 scopus 로고    scopus 로고
    • Drug evaluation: PTC-124: A potential treatment of cystic fibrosis and Duchenne muscular dystrophy
    • Hamed S. Drug evaluation: PTC-124: a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs. 2006;9(11):783-789.
    • (2006) Idrugs , vol.9 , Issue.11 , pp. 783-789
    • Hamed, S.1
  • 131
    • 50149098401 scopus 로고    scopus 로고
    • Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial
    • Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;372(9640):719-727.
    • (2008) Lancet , vol.372 , Issue.9640 , pp. 719-727
    • Kerem, E.1    Hirawat, S.2    Armoni, S.3
  • 132
    • 78349290383 scopus 로고    scopus 로고
    • Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis
    • Sermet-Gaudelus I, De Boeck K, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med. 2010;182(10):1262-1272.
    • (2010) Am J Respir Crit Care Med , vol.182 , Issue.10 , pp. 1262-1272
    • Sermet-Gaudelus, I.1    De Boeck, K.2    Casimir, G.J.3
  • 133
    • 84904016376 scopus 로고    scopus 로고
    • Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial
    • Kerem E, Konstan MW, De Boeck K, et al; Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014;2(7):539-547.
    • (2014) Lancet Respir Med , vol.2 , Issue.7 , pp. 539-547
    • Kerem, E.1    Konstan, M.W.2    De Boeck, K.3
  • 134
    • 0030154620 scopus 로고    scopus 로고
    • Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein
    • Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones. 1996;1(2):117-125.
    • (1996) Cell Stress Chaperones , vol.1 , Issue.2 , pp. 117-125
    • Brown, C.R.1    Hong-Brown, L.Q.2    Biwersi, J.3    Verkman, A.S.4    Welch, W.J.5
  • 135
    • 0030042386 scopus 로고    scopus 로고
    • Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation
    • Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem. 1996;271(2):635-638.
    • (1996) J Biol Chem , vol.271 , Issue.2 , pp. 635-638
    • Sato, S.1    Ward, C.L.2    Krouse, M.E.3    Wine, J.J.4    Kopito, R.R.5
  • 136
    • 0032871691 scopus 로고    scopus 로고
    • Butyrate increases apical membrane CFTR but reduces chloride secretion in MDCK cells
    • Moyer BD, Loffing-Cueni D, Loffing J, Reynolds D, Stanton BA. Butyrate increases apical membrane CFTR but reduces chloride secretion in MDCK cells. Am J Physiol. 1999;277(2):F271-F276.
    • (1999) Am J Physiol , vol.277 , Issue.2 , pp. F271-F276
    • Moyer, B.D.1    Loffing-Cueni, D.2    Loffing, J.3    Reynolds, D.4    Stanton, B.A.5
  • 137
    • 0030809817 scopus 로고    scopus 로고
    • Vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.
    • Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest. 1997;100(10):2457-2465.
    • (1997) J Clin Invest , vol.100 , Issue.10 , pp. 2457-2465
    • Rubenstein, R.C.1    Egan, M.E.2    Zeitlin, P.L.3
  • 138
    • 0034099743 scopus 로고    scopus 로고
    • Sodium 4-phenylbutyrate downregulates Hsc70: Implications for intracellular trafficking of ΔF508-CFTR
    • Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508-CFTR. Am J Physiol Cell Physiol. 2000;278(2):C259-C267.
    • (2000) Am J Physiol Cell Physiol , vol.278 , Issue.2 , pp. C259-C267
    • Rubenstein, R.C.1    Zeitlin, P.L.2
  • 139
    • 0031889082 scopus 로고    scopus 로고
    • Pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in Δ F508-homozygous cystic fibrosis patients
    • Rubenstein R, Zeitlin P. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in Δ F508-homozygous cystic fibrosis patients. Am J Respir Crit Care Med. 1998;157(2):484-490.
    • (1998) Am J Respir Crit Care Med , vol.157 , Issue.2 , pp. 484-490
    • Rubenstein, R.1    Zeitlin, P.A.2
  • 140
    • 46249118125 scopus 로고    scopus 로고
    • Correctors promote folding of the CFTR in the endoplasmic reticulum
    • Loo T, Bartlett M, Clarke D. Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem J. 2008;413(1):29-36.
    • (2008) Biochem J , vol.413 , Issue.1 , pp. 29-36
    • Loo, T.1    Bartlett, M.2    Clarke, D.3
  • 141
    • 33645530653 scopus 로고    scopus 로고
    • The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants
    • Loo T, Bartlett M, Wang Y, Clarke D. The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants. Biochem J. 2006;395(pt 3):537-542.
    • (2006) Biochem J , vol.395 , pp. 537-542
    • Loo, T.1    Bartlett, M.2    Wang, Y.3    Clarke, D.4
  • 142
    • 77950428804 scopus 로고    scopus 로고
    • Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis
    • Hutt DM, Herman D, Rodrigues APC, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol. 2010;6(1):25-33.
    • (2010) Nat Chem Biol , vol.6 , Issue.1 , pp. 25-33
    • Hutt, D.M.1    Herman, D.2    Rodrigues, A.3
  • 143
    • 79951829938 scopus 로고    scopus 로고
    • Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR
    • Sampson H, Robert R, Liao J, et al. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol. 2011;18(2):231-242.
    • (2011) Chem Biol , vol.18 , Issue.2 , pp. 231-242
    • Sampson, H.1    Robert, R.2    Liao, J.3
  • 144
    • 84884773595 scopus 로고    scopus 로고
    • VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1
    • Ren HY, Grove DE, De La Rosa O, et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell. 2013;24(19):3016-3024.
    • (2013) Mol Biol Cell , vol.24 , Issue.19 , pp. 3016-3024
    • Ren, H.Y.1    Grove, D.E.2    De La Rosa, O.3
  • 145
    • 81755163563 scopus 로고    scopus 로고
    • Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
    • Van Goor F, Hadida S, Grootenhuis PDJ, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 2011;108(46):18843-18848.
    • (2011) Proc Natl Acad Sci USA , vol.108 , Issue.46 , pp. 18843-18848
    • Van Goor, F.1    Hadida, S.2    Grootenhuis, P.3
  • 146
    • 84855202429 scopus 로고    scopus 로고
    • Results of a phase IIa study of VX-809, an investigational CFTR corrector compound
    • Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012;67(1):12-18.
    • (2012) Thorax , vol.67 , Issue.1 , pp. 12-18
    • Clancy, J.P.1    Rowe, S.M.2    Accurso, F.J.3
  • 147
    • 84904002908 scopus 로고    scopus 로고
    • VX09-809-102 Study Group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial
    • Boyle MP, Bell SC, Konstan MW, et al; VX09-809-102 Study Group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014;2(7):527-538.
    • (2014) Lancet Respir Med , vol.2 , Issue.7 , pp. 527-538
    • Boyle, M.P.1    Bell, S.C.2    Konstan, M.W.3
  • 148
    • 84937035647 scopus 로고    scopus 로고
    • Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR.
    • Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220-231.
    • (2015) N Engl J Med , vol.373 , Issue.3 , pp. 220-231
    • Wainwright, C.E.1    Elborn, J.S.2    Ramsey, B.W.3
  • 149
    • 84939225425 scopus 로고    scopus 로고
    • Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: Should we curb our enthusiasm?
    • Jones AM, Barry PJ. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Thorax. 2015;70(7):615-616.
    • (2015) Thorax , vol.70 , Issue.7 , pp. 615-616
    • Jones, A.M.1    Barry, P.J.2
  • 151
    • 84907223425 scopus 로고    scopus 로고
    • Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
    • Cholon DM, Quinney NL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med. 2014;6(246):246ra296.
    • (2014) Sci Transl Med , vol.6 , Issue.246
    • Cholon, D.M.1    Quinney, N.L.2    Fulcher, M.L.3
  • 152
    • 84907211027 scopus 로고    scopus 로고
    • Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
    • Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med. 2014;6(246):246ra297.
    • (2014) Sci Transl Med , vol.6 , Issue.246
    • Veit, G.1    Avramescu, R.G.2    Perdomo, D.3
  • 153
    • 84952021538 scopus 로고    scopus 로고
    • WS01.4 VX-661 in combination with ivacaftor in patients with cystic fibrosis and the F508del-CFTR mutation
    • Pilewski JM, Cooke J, Lekstrom-Himes J, Donaldson S. WS01.4 VX-661 in combination with ivacaftor in patients with cystic fibrosis and the F508del-CFTR mutation. J Cyst Fibros. 2015;14:S1.
    • (2015) J Cyst Fibros , vol.14
    • Pilewski, J.M.1    Cooke, J.2    Lekstrom-Himes, J.3    Donaldson, S.4
  • 154
    • 84982170519 scopus 로고    scopus 로고
    • WS01.2 QR-010, an RNA therapy, restores CFTR function using in vitro and in vivo models of delF508 CFTR
    • Beumer W, Swildens J, Henig N, et al. WS01.2 QR-010, an RNA therapy, restores CFTR function using in vitro and in vivo models of delF508 CFTR. J Cyst Fibros. 2015;14:S1.
    • (2015) J Cyst Fibros , vol.14
    • Beumer, W.1    Swildens, J.2    Henig, N.3
  • 155
    • 85073736996 scopus 로고    scopus 로고
    • QR-010, an RNA Therapy, Restores CFTR Function in the Saliva Secretion Assay
    • New York, NY: American Thoracic Society
    • Henig N, Beumer W, Anthonijsz H, et al. QR-010, an RNA Therapy, Restores CFTR Function in the Saliva Secretion Assay. A37. It Won’t be Long: Advances in Adult Cystic Fibrosis. New York, NY: American Thoracic Society; 2015:A1449-A1449.
    • (2015) A37. It Won’t Be Long: Advances in Adult Cystic Fibrosis , pp. A1449-A1449
    • Henig, N.1    Beumer, W.2    Anthonijsz, H.3
  • 156
    • 73249114731 scopus 로고    scopus 로고
    • Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
    • Van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009;106(44):18825-18830.
    • (2009) Proc Natl Acad Sci USA , vol.106 , Issue.44 , pp. 18825-18830
    • Van Goor, F.1    Hadida, S.2    Grootenhuis, P.3
  • 157
    • 78549279173 scopus 로고    scopus 로고
    • Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation
    • Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991-2003.
    • (2010) N Engl J Med , vol.363 , Issue.21 , pp. 1991-2003
    • Accurso, F.J.1    Rowe, S.M.2    Clancy, J.P.3
  • 158
    • 84885071273 scopus 로고    scopus 로고
    • Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: A randomised controlled trial
    • Davies J, Sheridan H, Bell N, et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med. 2013;1(8):630-638.
    • (2013) Lancet Respir Med , vol.1 , Issue.8 , pp. 630-638
    • Davies, J.1    Sheridan, H.2    Bell, N.3
  • 159
    • 80455162465 scopus 로고    scopus 로고
    • VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
    • Ramsey BW, Davies J, McElvaney NG, et al; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672.
    • (2011) N Engl J Med , vol.365 , Issue.18 , pp. 1663-1672
    • Ramsey, B.W.1    Davies, J.2    McElvaney, N.G.3
  • 160
    • 84911493956 scopus 로고    scopus 로고
    • Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
    • De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13(6):674-680.
    • (2014) J Cyst Fibros , vol.13 , Issue.6 , pp. 674-680
    • De Boeck, K.1    Munck, A.2    Walker, S.3
  • 161
    • 84958107856 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study
    • Davies JC, Cunningham S, Harris WT, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016;4(2):107-115.
    • (2016) Lancet Respir Med , vol.4 , Issue.2 , pp. 107-115
    • Davies, J.C.1    Cunningham, S.2    Harris, W.T.3
  • 162
    • 84865853894 scopus 로고    scopus 로고
    • VX 08-770-104 Study Group. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation
    • Flume PA, Liou TG, Borowitz DS, et al; VX 08-770-104 Study Group. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718-724.
    • (2012) Chest , vol.142 , Issue.3 , pp. 718-724
    • Flume, P.A.1    Liou, T.G.2    Borowitz, D.S.3
  • 163
    • 84992100293 scopus 로고    scopus 로고
    • WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco® in phase I clinical studies
    • Uttamsineh V, Pilja L, Grotbeck B, et al. WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco® in phase I clinical studies. J Cyst Fibros. 2016; 15(S1):S22.
    • (2016) J Cyst Fibros , vol.15
    • Uttamsineh, V.1    Pilja, L.2    Grotbeck, B.3
  • 164
    • 85043640362 scopus 로고    scopus 로고
    • QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis
    • Shamsah K, Jose A, Laurie D, et al. QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis. Am J Respir Crit Care Med. 2016;193:A7789.
    • (2016) Am J Respir Crit Care Med , vol.193
    • Shamsah, K.1    Jose, A.2    Laurie, D.3
  • 165
    • 85043637298 scopus 로고    scopus 로고
    • Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GPLG1837 in healthy volunteers
    • Vanhoutte FP, Gouy M, Haazen W, et al. Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GPLG1837 in healthy volunteers. Pediatr Pulmonol. 2015;50(S41):S289.
    • (2015) Pediatr Pulmonol , vol.50
    • Vanhoutte, F.P.1    Gouy, M.2    Haazen, W.3
  • 166
    • 77954939833 scopus 로고    scopus 로고
    • Hsp 70/Hsp 90 organizing protein as a nitrosylation target in cystic fibrosis therapy
    • Marozkina NV, Yemen S, Borowitz M, et al. Hsp 70/Hsp 90 organizing protein as a nitrosylation target in cystic fibrosis therapy. Proc Natl Acad Sci USA. 2010;107(25):11393-11398.
    • (2010) Proc Natl Acad Sci USA , vol.107 , Issue.25 , pp. 11393-11398
    • Marozkina, N.V.1    Yemen, S.2    Borowitz, M.3
  • 167
    • 84956899678 scopus 로고    scopus 로고
    • Augmentation of CFTR maturation by S-nitrosoglutathione reductase
    • Zaman K, Sawczak V, Zaidi A, et al. Augmentation of CFTR maturation by S-nitrosoglutathione reductase. Am J Physiol Lung Cell Mol Physiol. 2016;310(3):L263-L270.
    • (2016) Am J Physiol Lung Cell Mol Physiol , vol.310 , Issue.3 , pp. L263-L270
    • Zaman, K.1    Sawczak, V.2    Zaidi, A.3
  • 168
    • 33748944330 scopus 로고    scopus 로고
    • S-nitrosylating agents: A novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells
    • Zaman K, Carraro S, Doherty J, et al. S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells. Mol Pharmacol. 2006;70(4):1435-1442.
    • (2006) Mol Pharmacol , vol.70 , Issue.4 , pp. 1435-1442
    • Zaman, K.1    Carraro, S.2    Doherty, J.3
  • 169
    • 84969191949 scopus 로고    scopus 로고
    • The pharmacokinetics of N91115, an inhibitor of S-nitrosoglutathione reductase in cystic fibrosis patients
    • Taylor-Cousar J, Zemanick E, Solomon G. The pharmacokinetics of N91115, an inhibitor of S-nitrosoglutathione reductase in cystic fibrosis patients. Pediatr Pulmonol. 2015;50(S41):S285-S286.
    • (2015) Pediatr Pulmonol , vol.50 , pp. S285-S286
    • Taylor-Cousar, J.1    Zemanick, E.2    Solomon, G.3
  • 170
    • 85043642209 scopus 로고    scopus 로고
    • Amplifiers are a new class of CFTR modulators that increase the abundance of CFTR protein and combined with potentiators and correctors enhance chloride transport activity
    • Miller J, Drew L, Green O, et al. Amplifiers are a new class of CFTR modulators that increase the abundance of CFTR protein and combined with potentiators and correctors enhance chloride transport activity. Pediatr Pulmonol. 2015;50(S41):S265.
    • (2015) Pediatr Pulmonol , vol.50
    • Miller, J.1    Drew, L.2    Green, O.3
  • 171
    • 84961828393 scopus 로고    scopus 로고
    • Strategies in early clinical development for the treatment of basic defects of cystic fibrosis
    • Dhooghe B, Haaf JB, Noel S, Leal T. Strategies in early clinical development for the treatment of basic defects of cystic fibrosis. Expert Opin Investig Drugs. 2016;25(4):423-436.
    • (2016) Expert Opin Investig Drugs , vol.25 , Issue.4 , pp. 423-436
    • Dhooghe, B.1    Haaf, J.B.2    Noel, S.3    Leal, T.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.